Integrated network pharmacology and comprehensive bioinformatics analysis to identify the mechanisms and molecular targets of ketamine in ischemic stroke–depression comorbidity
Fig 5
Expression of hub genes in ischemic stroke training(a) GSE16561 and validation (b) GSE58294 sets.
X- and y-axes represent genes and expression levels, respectively. p-values were estimated by the Wilcoxon rank-sum test: *p < 0.05, ***p < 0.001, ****p < 0.0001). Expression of hub genes in depression training (c) (GSE23848) and validation (d) (GSE76826) sets. X- and y-axes represent genes and expression levels, respectively. p-values were estimated by the Wilcoxon rank-sum test: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Receiver operating characteristic (ROC) curves of hub genes in ischemic stroke training (e) GSE16561 and validation (f) GSE58294 sets. X- and y-axes represent false and true positive rates, respectively. ROC curves of feature genes in depression training (g) GSE23848 and validation (h) GSE76826 sets. X- and y-axes represent false and true positive rates, respectively.